These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 9485094)

  • 1. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone.
    Garnero P; Fledelius C; Gineyts E; Serre CM; Vignot E; Delmas PD
    J Bone Miner Res; 1997 Sep; 12(9):1407-15. PubMed ID: 9286756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy.
    Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Echevarría M; Ros I; Ballesta AM; Muñoz-Gómez J
    J Bone Miner Metab; 2002; 20(2):116-20. PubMed ID: 11862534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
    Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
    J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of bone disease using isomerized and racemized fragments of type I collagen.
    Cloos PA; Fledelius C; Christgau S; Christiansen C; Engsig M; Delmas P; Body JJ; Garnero P
    Calcif Tissue Int; 2003 Jan; 72(1):8-17. PubMed ID: 12384813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical assessment of Paget's disease of bone.
    Shankar S; Hosking DJ
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P22-7. PubMed ID: 17229003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone.
    Garnero P; Christgau S; Delmas PD
    Bone; 2001 May; 28(5):461-4. PubMed ID: 11344044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations.
    Garnero P; Schott AM; Prockop D; Chevrel G
    Bone; 2009 Mar; 44(3):461-6. PubMed ID: 19071236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.
    Garnero P; Cloos P; Sornay-Rendu E; Qvist P; Delmas PD
    J Bone Miner Res; 2002 May; 17(5):826-33. PubMed ID: 12009013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
    Garnero P; Gineyts E; Arbault P; Christiansen C; Delmas PD
    J Bone Miner Res; 1995 Apr; 10(4):641-9. PubMed ID: 7610936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
    Bonde M; Garnero P; Fledelius C; Qvist P; Delmas PD; Christiansen C
    J Bone Miner Res; 1997 Jul; 12(7):1028-34. PubMed ID: 9200001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
    Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
    Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
    Papapoulos SE; Frölich M
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The renal clearance of free and peptide-bound deoxypyridinoline: response to pamidronate treatment of Paget's disease.
    Naylor KE; Jackson B; Eastell R
    J Bone Miner Res; 2003 Apr; 18(4):658-61. PubMed ID: 12674326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.
    Randall AG; Kent GN; Garcia-Webb P; Bhagat CI; Pearce DJ; Gutteridge DH; Prince RL; Stewart G; Stuckey B; Will RK; Retallack RW; Price RI; Ward L
    J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
    Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ
    J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical markers of bone turnover in Paget's disease of bone.
    Delmas PD
    J Bone Miner Res; 1999 Oct; 14 Suppl 2():66-9. PubMed ID: 10510216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone.
    Cloos PA; Lyubimova N; Solberg H; Qvist P; Christiansen C; Byrjalsen I; Christgau S
    Clin Lab; 2004; 50(5-6):279-89. PubMed ID: 15209436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.